CoChat
Sign Up
Cited by 142Smoking Behavior and CessationPharmacovigilance and Adverse Drug ReactionsSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Varenicline, Smoking Cessation, and Neuropsychiatric Adverse Events

Open access
Gibbons, Robert D., Mann, J. John·2013·American Journal of Psychiatry
DOI 10.1176/appi.ajp.2013.12121599PMC PMC4238282
Open this paper in CoChat — free account

Abstract

OBJECTIVE: In 2009, the U.S. Food and Drug Administration issued a black box warning for varenicline regarding neuropsychiatric events. The authors used data from randomized controlled trials and from a large Department of Defense (DOD) observational study to assess the efficacy and safety of varenicline. METHOD: The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders. The authors also analyzed a large DOD data set to compare acute (30-day and 60-day) rates of neuropsychiatric adverse events in patients receiving varenicline or nicotine replacement therapy (N=35,800) and to assess reports of anxiety, mood, and psychotic symptoms and disorders, other mental disorders, and suicide attempt. RESULTS: In the randomized controlled trials, varenicline increased the risk of nausea (odds ratio=3.69, 95% CI=3.03-4.48) but not rates of suicidal events, depression, or aggression/agitation. It significantly increased the abstinence rate, by 124% compared with placebo and 22% compared with bupropion. Having a current or past psychiatric illness increased the risk of neuropsychiatric events equally in treated and placebo patients. In the DOD study, after propensity score matching, the overall rate of neuropsychiatric disorders was significantly lower for varenicline than for nicotine replacement therapy (2.28% compared with 3.16%). CONCLUSIONS: This analysis revealed no evidence that varenicline is associated with adverse neuropsychiatric events. The evidence supports the superior efficacy of varenicline relative to both placebo and bupropion, indicating considerable benefit without evidence of risk of serious neuropsychiatric adverse events, in individuals with and without a recent history of a psychiatric disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2013.12121599

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 2

  1. Cahill K, 2012, Cochrane Database Syst Rev, 4, CD006103
  2. Hedeker D, 2008, SuperMix: A Program for Mixed-Effects Regression Models

Cited by

Sorted by citations

Items 101–142 of 142

Related

See all

Metadata

Authors
Gibbons, R. D., & Mann, J. J.
Affiliations
University of Chicago (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2013-12
Volume
170
Issue
12
Pages
1460-1467
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.2013.12121599
PMC
PMC4238282
OpenAlex
W2101931786
Cited by
142
References
17
Citations by year
2026: 3 · 2024: 2 · 2023: 6 · 2021: 29 · 2020: 10 · 2019: 4 · 2018: 7 · 2017: 10 · 2016: 23 · 2015: 28 · 2014: 16 · 2013: 3
FWCI
16.25
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Justice
  • Pfizer
  • National Institute of Mental Health (MH8012201, MH-062185, P50MH062185)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
varenicline, smoking cessation, neuropsychiatric adverse effects, black box warning, nicotine replacement therapy, bupropion, smoking abstinence, suicidal ideation, depression, aggression, nausea, mental illness, military personnel, drug safety
MeSH terms
Varenicline, Adult, Aggression, Mental Disorders, Benzazepines, Depression, Female, Humans, Male, Nausea, Psychomotor Agitation, Quinoxalines, Risk Factors, Suicide, Attempted, Randomized Controlled Trials as Topic, Smoking Cessation, Bupropion, Treatment Outcome, Akathisia, Drug-Induced, Suicidal Ideation, Tobacco Use Cessation Devices, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review